GEN Exclusives

More »

Feature Articles

More »
Apr 1, 2010 (Vol. 30, No. 7)

Hopes Dashed for Alzheimer's Patients

The Latest Phase III Failure Perpetuates Skepticism about Developing Drugs for AD

  • Success Continues to Be Evasive

    While Flurizan was expected to treat the underlying causes of the disease, the four currently marketed treatments simply alleviate symptoms. Several drugs that aim to prevent plaque production are in Phase III trials.

    No one believes that developing new AD drugs is easy; over 20 have failed Phase III since 2002. AD patients and their physicians, however, are ill-served by the uber-hype engendered by results from poorly controlled clinical trials and pharma company tap dancing.


Readers' Comments

Posted 11/09/2010 by jaypee costal

Alzheimer's disease treatments using omega-3 products were proven ineffective in a study released Tuesday. I found this here: <a title="Medical test eliminates omega-3 benefit for Alzheimer’s" href="http://personalmoneystore.com/moneyblog/2010/11/02/omega-3-fish-oil-alzheimers/">Omega-3 fish oil fails to slow Alzheimer's, study says</a> The study, which sought to demonstrate how omega-3 fatty acids could impede the progress of dementia, could not. Omega-3 fish-oil has been touted as a treatment for Alzheimer’s because individuals with a diet rich in fish demonstrate a lesser tendency to suffer from dementia .

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?